Advertisement
Abstract| Volume 92, SUPPLEMENT 1, S22, March 2018

CD73 activity and outcome of advanced melanoma patients treated with nivolumab

DOI:https://doi.org/10.1016/j.ejca.2018.01.053
CD73 activity and outcome of advanced melanoma patients treated with nivolumab
Previous ArticleHow cancer specific T-cell recognition and functionality is affected by combination of radio- and immunotherapeutic strategies
Next ArticleImmuno-related adverse events from check-point inhibitors during immune-therapy for cancer. Imaging findings
      Background: Nivolumab is an anti-PD1 agent used to treat patients with advanced melanoma. Here we report the CD73 enzymatic activity in melanoma patients receiving nivolumab. CD73 is an enzyme involved in the generation of adenosine, a metabolic mediator that potently suppresses anti-tumor T-cell responses.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      Article info

      Publication history

      P08.02

      Identification

      DOI: https://doi.org/10.1016/j.ejca.2018.01.053

      Copyright

      © 2018 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX